BIOMACS II

(redirected from Biochemical Markers in Acute Coronary Syndromes)

BIOMACS II

Biochemical Markers in Acute Coronary Syndromes. A pilot trial that evaluated the effect of a low-molecular weight heparin (dalteparin), as an adjuvant to thrombolysis in patients with acute MI.
 
Primary endpoints
Proportion of patients with successful reperfusion, recurrent ischemia, patency at 24 hours.

Conclusion
Dalteparin added to streptokinase tended to provide a higher rate of TIMI grade-3 flow in infarct-related artery compared with placebo; there were also fewer recurrent ischaemic episodes 6 to 24 hours after treatment, per Holter monitoring in the dalteparin group.

Logistics
Randomised, placebo-controlled; 101 patients, dalteparin or placebo given just before streptokinase; a second injection of dalteparin or placebo was administered 12 hours after the initial dose.
References in periodicals archive ?
[5.] Christenson RH (2007) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Utilization of Biochemical Markers in Acute Coronary Syndromes and Heart Failure.
National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115:e356-75.
Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage.
Use of biochemical markers in acute coronary syndromes: IFCC scientific division, committee on standardization of markers of cardiac damage.
The articles presented here provide the NACB's updated recommendations for the rapidly evolving topics of Clinical Utilization of Biochemical Markers in Acute Coronary Syndromes and Analytical Issues for Biochemical Markers of Acute Coronary Syndromes.
Use of biochemical markers in acute coronary syndromes. Clin Chem Lab Med 1999;37:687-93.
Full browser ?